Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment
This is Dermata's first issued U.S. patent for XYNGARI™, which uses its Spongilla technology to topically treat acne -- Dermata expects to announce topline results from its STAR-1 Phase 3 XYNGARI™ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback